DNA damage inducers, i.e., genotoxins, are some of the most effective agents in cancer therapy. Persistent damage to the genomic DNA can activate programmed cell death. Therefore, fundamental understanding of genotoxin-induced cell death mechanisms holds the promise of enhancing the efficacy of cancer therapeutics. The varied responses of tumors to genotoxins are a reflection of the variable death responses to DNA damage among different normal cell types, which suggest developmental programs may set different thresholds for damage signals to trigger death. Studies from our laboratory have identified the nuclear Abl tyrosine kinase as a developmental context-dependent activator of cell death to DNA damage. Through tyrosine phosphorylation of the C-terminal repeated domain (CTD) of RNA polymerase II, we have found that Abl regulates RNA splicing in genotoxin-treated cells. The human genome contains approximately twenty thousand genes but encodes many more proteins through the alternative usage of variable exons. Alternative splicing has been shown to generate pro-death and anti-death protein isoforms from a single gene, underscoring the importance of splicing regulation in programmed cell death. There has not been a systematic study of the effects of genotoxins on alternative splicing. The proposed study will fill this gap by pursuing the splicing regulatory function of nuclear Abl. Specifically, we will (1) delineate the role of Abl in the alternative splicing of the CD44 gene, because we have found that activation of Abl leads to the exclusion of CD44 variable exons 4 and 5 in doxorubicin-treated cells;(2) conduct a large-scale survey of DNA damage-induced and Abl-dependent alternative splicing of several thousand genes using a fiber-optic bead array-based technology;(3) identify DNA damage-induced genomic binding sites for Abl using the human genome tiling arrays, because we have found that doxorubicin causes an enhanced association of Abl with the CD44 variable exon 5;(4) investigate the role of alternative splicing in cell death response to DNA damage by testing the hypothesis that doxorubicin specifically reduces the levels of CD44 variants to enhance death receptor-induced cell killing;and (5) construct mouse tumor models to investigate the role of nuclear Abl in tumor responses to chemotherapy. The proposed research will investigate a previously unappreciated effect of DNA damage on RNA splicing, through a previously unknown mechanism of splicing regulation by CTD tyrosine phosphorylation. Because Abl is not mutated in sporadic human cancers and because Abl can activate p53-independent cell death, results from the proposed research will shed light on how to exploit the pro-apoptotic function of nuclear Abl to kill tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043054-26
Application #
8206811
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Hildesheim, Jeffrey
Project Start
1986-08-01
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2014-01-31
Support Year
26
Fiscal Year
2012
Total Cost
$398,601
Indirect Cost
$140,607
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hu, Wan-Hsiang; Miyai, Katsumi; Sporn, Judith C et al. (2016) Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm. J Clin Pathol 69:627-31
Pineda, Gabriel; Shen, Zhouxin; de Albuquerque, Claudio Ponte et al. (2015) Proteomics studies of the interactome of RNA polymerase II C-terminal repeated domain. BMC Res Notes 8:616
Suknuntha, Kran; Ishii, Yuki; Tao, Lihong et al. (2015) Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res 15:678-93
Tu, Chi-Chiang; Zhong, Yan; Nguyen, Louis et al. (2015) The kinase ABL phosphorylates the microprocessor subunit DGCR8 to stimulate primary microRNA processing in response to DNA damage. Sci Signal 8:ra64
Ishii, Yuki; Nhiayi, May Keu; Tse, Edison et al. (2015) Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. PLoS One 10:e0140585
Tonino, Sanne H; Mulkens, Chantal E; van Laar, Jacoline et al. (2015) Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. Leuk Lymphoma 56:2439-47
de Souza, Jorge E S; Fonseca, André F; Valieris, Renan et al. (2014) S-score: a scoring system for the identification and prioritization of predicted cancer genes. PLoS One 9:e94147
Manthey, Carolin F; Calabio, Christine B; Wosinski, Anna et al. (2014) Indispensable functions of ABL and PDGF receptor kinases in epithelial adherence of attaching/effacing pathogens under physiological conditions. Am J Physiol Cell Physiol 307:C180-9
Wang, Jean Y J (2014) The capable ABL: what is its biological function? Mol Cell Biol 34:1188-97
Sridevi, Priya; Nhiayi, May K; Setten, Ryan L et al. (2013) Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine. PLoS One 8:e77495

Showing the most recent 10 out of 66 publications